Onca Bio
Onca Bio is a biotechnology company developing novel therapeutic candidates for oncology and immuno-oncology, with a focus on precision medicine approaches that match patients to treatments based on tumor biomarkers and molecular pathways. The company's research-driven pipeline targets high-need cancer indications where existing immunotherapies and targeted treatments have limited efficacy.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Founders
Founder details are not available yet.
Product
Problem
Despite advances in cancer treatment, many patients continue to face limited therapeutic options, particularly those with tumors that do not respond to existing immunotherapies or targeted treatments. The heterogeneity of cancer biology demands more precise, biomarker-driven approaches to identify patients most likely to benefit from specific therapies.
Solution
Onca Bio is a biotechnology company developing innovative therapeutic candidates designed to address unmet needs in oncology. The company leverages a deep understanding of tumor biology and the immune system to create novel treatments that target specific molecular pathways involved in cancer progression. Its pipeline is focused on advancing precision medicine strategies that match patients with therapies based on tumor characteristics. The company is committed to translating scientific discoveries into clinical-stage assets that have the potential to meaningfully improve outcomes for cancer patients.
Target Audience
Onca Bio's primary stakeholders include biopharmaceutical partners, academic research institutions, and, ultimately, patients with cancer who may benefit from its pipeline of precision therapies.
Features
- Focus on oncology and immuno-oncology therapeutic development
- Precision medicine approach targeting specific cancer biomarkers and pathways
- Pipeline of novel therapeutic candidates for high-need indications
- Research-driven strategy rooted in tumor biology and immunology